CVM
AMEXCel-Sci Corporation
Website
News25/Ratings0
News · 26 weeks16+100%
2025-10-262026-04-19
Mix790d
- Insider4(57%)
- SEC Filings2(29%)
- Other1(14%)
Latest news
25 items- SECSEC Form S-1 filed by Cel-Sci CorporationS-1 - CEL SCI CORP (0000725363) (Filer)
- INSIDERSEC Form 4 filed by Talor Eyal4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Prichep Patricia B4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERSEC Form 4 filed by Kersten Geert R4 - CEL SCI CORP (0000725363) (Issuer)
- PRCEL-SCI Reports Fiscal First Quarter 2026 ResultsSet to Commence Patient Enrollment Summer of 2026 in Pivotal U.S. FDA Head and Neck Cancer Registration Study Entering Saudi Oncology Market, Potentially Through Key Partnerships to Advance Multikine Approval and Commercialization CEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments. "CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia. We plan to commence enrollment this summer in our
- SECSEC Form 10-Q filed by Cel-Sci Corporation10-Q - CEL SCI CORP (0000725363) (Filer)
- INSIDERChief Executive Officer Kersten Geert R bought $200,001 worth of shares (38,023 units at $5.26), increasing direct ownership by 46% to 120,815 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Scientific Officer Talor Eyal was granted 456 shares, increasing direct ownership by 8% to 6,264 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Financial Officer Prichep Patricia B was granted 815 shares, increasing direct ownership by 7% to 12,028 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Executive Officer Kersten Geert R was granted 998 shares, increasing direct ownership by 1% to 82,792 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- PRCEL-SCI Reports Fiscal 2025 ResultsFiled for Breakthrough Designation for Multikine in Saudi Arabia A 212-patient Confirmatory Registration Study for Multikine in PD-L1 low newly diagnosed head and neck cancer patients is currently in final stage of preparations - enrollment expected to begin Spring 2026 Plans to seek early approval in U.S. based on pre-surgical response rate upon full enrollment CEL-SCI Corporation (NYSE:CVM) reported financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments. "During fiscal 2025, our regulatory advancements accelerated driven by new opportunities for Multikine in Saudi Arabia and the green light we have received for our Co
- INSIDERChief Executive Officer Kersten Geert R bought $49,998 worth of shares (8,389 units at $5.96), increasing direct ownership by 11% to 81,794 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- SECSEC Form EFFECT filed by Cel-Sci CorporationEFFECT - CEL SCI CORP (0000725363) (Filer)
- SECCel-Sci Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - CEL SCI CORP (0000725363) (Filer)
- SECSEC Form S-3 filed by Cel-Sci CorporationS-3 - CEL SCI CORP (0000725363) (Filer)
- SECCel-Sci Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - CEL SCI CORP (0000725363) (Filer)
- INSIDERChief Scientific Officer Talor Eyal was granted 260 shares, increasing direct ownership by 5% to 5,808 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Financial Officer Prichep Patricia B was granted 466 shares, increasing direct ownership by 4% to 11,213 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- INSIDERChief Executive Officer Kersten Geert R was granted 570 shares, increasing direct ownership by 0.78% to 73,405 units (SEC Form 4)4 - CEL SCI CORP (0000725363) (Issuer)
- SECSEC Form S-8 filed by Cel-Sci CorporationS-8 - CEL SCI CORP (0000725363) (Filer)
- SECCel-Sci Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Announces Closing of $10 Million Public OfferingCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its offering of 1,111,200 shares of its common stock. Each share of common stock was sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $10 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. The securities were offered and sold pursuant to
- SECSEC Form 424B5 filed by Cel-Sci Corporation424B5 - CEL SCI CORP (0000725363) (Filer)
- PRCEL-SCI Announces Pricing of $10 Million Public OfferingCEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock. Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate
- SECSEC Form 424B5 filed by Cel-Sci Corporation424B5 - CEL SCI CORP (0000725363) (Filer)